Combining a chimeric antigen receptor and a conventional T-cell receptor to generate T cells expressing two additional receptors (TETARs) for a multi-hit immunotherapy of melanoma

Experimental Dermatology

Volumn 25, Issue 11, 2016, Pages 872-879

  Uslu, Ugur ^a   Schuler, Gerold ^a   Dörrie, Jan ^a   Schaft, Niels ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Adoptive T cell therapy; Cancer; Human; Immune escape; Immunotherapy

Indexed keywords

ANTI MELANOMA ASSOCIATED CHONDROITIN SULPHATE PROTEOGLYCAN; CHIMERIC ANTIGEN RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; MELANOCYTE PROTEIN PMEL 17; MESSENGER RNA; PROTEOCHONDROITIN SULFATE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CYTOKINE; HMW-MAA; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOWN REGULATION; ELECTROPORATION; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; NONVIRAL GENE DELIVERY SYSTEM; PROTEIN EXPRESSION; TARGET CELL; TUMOR ESCAPE; ADOPTIVE IMMUNOTHERAPY; EVALUATION STUDY; GENETIC TRANSFECTION; GENETICS; METABOLISM; NORMAL HUMAN; PROCEDURES; TRANSPLANTATION;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; GP100 MELANOMA ANTIGEN; HEALTHY VOLUNTEERS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; MELANOMA; RECEPTORS, ANTIGEN, T-CELL; TRANSFECTION;

EID: 84980324608     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.13095     Document Type: Article

References (48)

1. Grupp SA, Kalos M, Barrett D, et al. N Engl J Med. 2013;368:1509–1518.
2. Johnson LA, Scholler J, Ohkuri T, et al. Sci Transl Med. 2015;7:275ra22.
3. Beatty GL, Haas AR, Maus MV, et al. Cancer Immunol Res. 2014;2:112–120.
4. Barrett DM, Grupp SA, June CH. J Immunol. 2015;195:755–761.
5. Davis MM, Bjorkman PJ. Nature. 1988;334:395–402.
6. Gross G, Waks T, Eshhar Z. Proc Natl Acad Sci U S A. 1989;86:10024–10028.
7. Eshhar Z, Waks T, Gross G. Cancer J. 2014;20:123–126.
8. Hombach A, Wieczarkowiecz A, Marquardt T, et al. J Immunol. 2001;167:6123–6131.
9. Anurathapan U, Leen AM, Brenner MK, et al. Cytotherapy. 2014;16:713–733.
10. Bonini C, Brenner MK, Heslop HE, et al. Biol Blood Marrow Transplant. 2011;17:S15–S20.
11. Gill S, Kalos M. Transl Res. 2013;161:365–379.
12. Wieczorek A, Uharek L. Transfus Med Hemother. 2013;40:388–402.
13. Park TS, Rosenberg SA, Morgan RA. Trends Biotechnol. 2011;29:550–557.
14. Maus MV, Grupp SA, Porter DL, et al. Blood. 2014;123:2625–2635.
15. Davila ML, Bouhassira DC, Park JH, et al. Int J Hematol. 2014;99:361–371.
16. Lamers CH, Sleijfer S, van Steenbergen SS, et al. Mol Ther 2013;21:904–912.
17. Linette GP, Stadtmauer EA, Maus MV, et al. Blood. 2013;122:863–871.
18. Zhao Y, Zheng Z, Robbins PF, et al. J Immunol. 2005;174:4415–4423.
19. Zhao Y, Zheng Z, Cohen CJ, et al. Mol Ther. 2006;13:151–159.
20. Schaft N, Dorrie J, Muller I, et al. Cancer Immunol Immunother. 2006;55:1132–1141.
21. Birkholz K, Hofmann C, Hoyer S, et al. J Immunol Methods. 2009;346:45–54.
22. Zhao Y, Moon E, Carpenito C, et al. Cancer Res. 2010;70:9053–9061.
23. Krug C, Birkholz K, Paulus A, et al. Cancer Immunol Immunother. 2015;64:1623–1635.
24. Barrett DM, Zhao Y, Liu X, et al. Hum Gene Ther. 2011;22:1575–1586.
25. Poggi A, Musso A, Dapino I, et al. Immunol Lett. 2014;159:55–72.
26. Dunn GP, Bruce AT, Ikeda H, et al. Nat Immunol. 2002;3:991–998.
27. Marchand M, Brichard V, van Baren N, et al. Expert Opin Biol Ther. 2001;1:497–510.
28. Mendez R, Rodriguez T, Del Campo A, et al. Cancer Immunol Immunother. 2008;57:719–729.
29. Seliger B, Maeurer MJ, Ferrone S. Immunol Today. 2000;21:455–464.
30. Tao J, Li Y, Liu YQ, et al. Br J Dermatol. 2008;158:88–94.
31. Hofmann C, Hofflin S, Huckelhoven A, et al. Blood. 2011;118:5174–5177.
32. Hofflin S, Prommersberger S, Uslu U, et al. Cancer Biol Ther. 2015;16:1323–1331.
33. Campoli MR, Chang CC, Kageshita T, et al. Crit Rev Immunol. 2004;24:267–296.
34. Chekenya M, Rooprai HK, Davies D, et al. Int J Dev Neurosci. 1999;17:421–435.
35. Godal A, Bruland O, Haug E, et al. Br J Cancer. 1986;53:839–841.
36. Rosenberg SA, Zhai Y, Yang JC, et al. J Natl Cancer Inst. 1998;90:1894–1900.
37. Burns WR, Zhao Y, Frankel TL, et al. Cancer Res. 2010;70:3027–3033.
38. Schaft N, Dorrie J, Thumann P, et al. J Immunol. 2005;174:3087–3097.
39. Gladow M, Uckert W, Blankenstein T. Eur J Immunol. 2004;34:1882–1891.
40. Murphy A, Westwood JA, Brown LE, et al. Cancer Gene Ther. 2007;14:499–508.
41. Heemskerk MH, Hoogeboom M, Hagedoorn R, et al. J Exp Med. 2004;199:885–894.
42. Carretero R, Romero JM, Ruiz-Cabello F, et al. Immunogenetics. 2008;60:439–447.
43. Spiotto MT, Yu P, Rowley DA, et al. Immunity. 2002;17:737–747.
44. June CH, Maus MV, Plesa G, et al. Cancer Immunol Immunother. 2014;63:969–975.
45. Davis MM, Krogsgaard M, Huse M, et al. Annu Rev Immunol. 2007;25:681–695.
46. Birnbaum ME, Berry R, Hsiao YS, et al. Proc Natl Acad Sci U S A. 2014;111:17576–17581.
47. Bialer G, Horovitz-Fried M, Ya’acobi S, et al. J Immunol 2010;184:6232–6241.
48. Cohen CJ, Zhao Y, Zheng Z, et al. Cancer Res. 2006;66:8878–8886.